Difficulty concentrating and memory problems are common symptoms of Long COVID. Affected people can, for example, no longer remember the content of a telephone conversation after a short time, or their thinking feels slowed down. This can lead to problems in the private life as well as at work, which then leads to further issues.
The University of Basel is now conducting a drug study for this symptom complex. The aim is to test whether a particular drug can improve cognitive performance. The drug, which is used to improve walking ability in multiple sclerosis (MS), is largely free of undesirable side effects at this dosage.
"We're hoping for positive effects and now we want to study whether they actually occur."
This is a so-called proof-of-concept study. Study leader Prof. Dominique de Quervain explains: "In this first phase, we are checking whether the substance produces fundamentally positive effects." If the results are good, a larger and longer study will then be conducted.
Demanding requirements
For those interested, there are some requirements to consider. Participants should be between 18 and 60 years old and have a good knowledge of German. In addition, a total of five test days has to be completed at the University of Basel, each of which lasts six to seven hours, including breaks. During those days, cognitive tests have to be completed. "The study is therefore less suitable for people suffering from severe fatigue or PEM (post-exertional malaise)," says de Quervain.
Years of research behind it
The team at the University of Basel has been researching the mechanism of action in question for some time and therefore has reason to believe that the compound under investigation could alleviate the cognitive symptoms of Long COVID. "Of course, we hope to find a positive effect," says Dominique de Quervain. Because the medication is already on the market, it could be comparatively quick before it can be prescribed. "Currently, however, it can and should be taken exclusively in the context of studies," says de Quervain.
If the research shows positive results in practice, it could alleviate an important symptom of Long COVID. Even if it is not a curative therapy, it would be a great relief for many affected people.
Show
